Skip to main content
Clinical Trials/NCT00600301
NCT00600301
Withdrawn
Phase 3

Vitrectomy Without Internal Limiting Membrane Removal in the Treatment of Diffuse Diabetic Macular Edema: a Comparative Kenalog Vs Bevacizumab Intravitreal Injection Vs Control Study

Asociación para Evitar la Ceguera en México1 site in 1 countryJanuary 2008

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Diffuse Diabetic Macular Edema
Sponsor
Asociación para Evitar la Ceguera en México
Locations
1
Status
Withdrawn
Last Updated
last year

Overview

Brief Summary

Diabetic macular edema is the most common cause of visual loss among patients with diabetic retinopathy. Pars plana vitrectomy has been reported to be effective for the treatment of diabetic macular edema. Previous report showed a limited improvement in visual acuity and macular thickness posterior intraoperative triamcinolone acetonide. Bevacizumab intravitreal injection has been proven be effective in the treatment of diabetic macular edema, in recent publications. The purpose of this study is to evaluate whether vitrectomy with and without intravitreal triamcinolone acetonide and bevacizumab injection affects vision outcome and macular thickness in patients with diabetic macular edema.

Registry
clinicaltrials.gov
Start Date
January 2008
End Date
January 2008
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Asociación para Evitar la Ceguera en México
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Diffuse diabetic macular edema
  • Non proliferative diabetic retinopathy
  • No VPP previa
  • No previous treament with laser, Triamcinolone acetonide, and Bevacizumab

Exclusion Criteria

  • Proliferative diabetic retinopathy
  • Previous pars plana vitrectomy
  • Previous treatment with diabetic macular edema
  • Focal macular edema
  • Macular Ischemia

Outcomes

Primary Outcomes

Not specified

Study Sites (1)

Loading locations...

Similar Trials